The new office will give clients access to the company's services in the Chinese market.
PharmaLex Group, a provider of specialized services for the pharma, biotech, and medtech industries worldwide, has announced the opening of a new branch in Beijing, China, giving global clients access to a team of regulatory experts in the region.
As of September 2022, the newly established PharmaLex Beijing team, which includes personnel joining from Bayer China, will be offering pharmacovigilance, regulatory affairs, development consulting, and quality management to global clients bringing products to the China market. PharmaLex China will also be the local contact point for Chinese-based biopharmaceutical companies that are developing pharmaceuticals or medical devices with a goal of entering the European or US markets.
Continue reading here.
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.